Affimed NV: Up on dosing first patient in early-stage cancer therapy study

Affimed NV

06/10/2020 13:25

** Shares of biopharmaceutical co  AFMD.O  up 9.3% at $3.8
premarket 
    ** Co announces dosing of first patient in Phase 1 clinical
trial of cord blood-derived Natural Killer (NK) cells with an
innate cell engager (ICE)  urn:newsml:reuters.com:*:nGNE2JR9V2
    ** Cord blood is blood that remains in placenta
    ** First of its kind clinical study combining NK cell
product with an ICE
    ** An NK cell armed with antibody AFM13 (ICE) is designed to
direct NK cells to tumor site in order to target cancer cells
    ** "Pre-loading innate immune cells with an ICE takes this
idea a step further and potentially intensifies the treatment's
effect, especially in patients who have an impaired immune
system or low NK cell numbers" - Chief Medical Officer
    ** Up to Monday's close, stock up ~29% YTD 

 (Reporting by Shivani Kumaresan in Bengaluru)
 ((Shivani.Kumaresan@thomsonreuters.com ; +1 646 223 8780;))